GT Biopharma (GTBP) Appoints Presents Data Supporting Rademikibart

GT Biopharma, Inc. (the “Company”) (NASDAQ: GTBP) today announced the appointment of c of Directors.

“We are very pleased to welcome David to the Board of Directors. David is an experienced senior executive with global connections and a proven track record of success in working with corporate management teams,” said Michael Breen, Executive Chairman and Chief Executive Officer of GT Biopharma. “His guidance and perspective will be invaluable as we approach our first data readout this year for GTBP-3650 and look to expand the rest of our NK-engager pipeline into broader indications in 2026.”

Mr. Mun-Gavin has several decades of executive leadership experience at the very highest levels. He has served as the Client Director, International Private Banking Division, of several global private banks. The global institutions where Mr Mun-Gavin has worked include Credit Suisse, Swiss Bank Corporation Investment Banking Ltd., and Bankers Trust International Limited.

Mr. Mun-Gavin has also served in other management roles, including several years as CEO of the Vanol Group, an international oil trading company.

Mr. Mun-Gavin is a qualified Chartered Accountant (SA) and worked for Goldby, Compton and Mackelvie during his accountancy career.

You May Also Be Interested In